A Phase 2 interventional study of Palbociclib and Cetuximab in Head and Neck Squamous Cell Carcinoma, sponsored by Washington University School of Medicine. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine — 6 open to participants now, 12 under way, 1 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Washington University School of Medicine.
Among the 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine, this one is the 20th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2018, is one of 16 in phase 2, reaches primary completion later than 0 of the 11 other live ones, and was the 10th registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →6 of the 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 20 · Phase 3 1
First in 2008; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 43 across the 23 interventional studies, 0 across the 1 observational. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
3 of the studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04831320Washington University School of MedicineNab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | 2027-06-30 |
| NCT05980000Washington University School of MedicineRamucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma | 2027-06-30 |
| NCT04852328Washington University School of MedicineThree Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Squamous Cell Carcinoma of Head and Neck by Washington University School of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the results of treating patients with HPV-unrelated head and neck squamous cell carcinoma with neoadjuvant single-agent palbociclib, followed by chemoradiation (either cisplatin + IMRT or cetuximab + IMRT depending on patient characteristics), followed by adjuvant single-agent palbociclib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Normal bone marrow function as defined below:
Additional Cohort 1 Eligibility Criteria: Patients enrolling to Cohort 1 must meet all of the following criteria:
Adequate organ function defined as:
Additional Cohort 2 Eligibility Criteria: Patients enrolling to Cohort 2 must meet at least one of the following criteria:
Reduced organ function defined as:
Exclusion Criteria:
Treated within the last 7 days prior to Day 1 of protocol therapy with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles) * Step 2: Cisplatin 100 mg/m\^2 given on Days 1 and 22 with accelerated IMRT 70 Gy to be administered over 6 weeks * Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cisplatin \& IMRT
Drug: Palbociclib · Drug: Cisplatin · Radiation: Intensity-Modulated Radiation Therapy · Procedure: Tumor biopsy · Procedure: Peripheral blood draw
* Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles) * Step 2: Cetuximab given one week before RT and then weekly with accelerated IMRT 70 Gy to be administered over 6 weeks * Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cetuximab \& IMRT
Drug: Palbociclib · Drug: Cetuximab · Radiation: Intensity-Modulated Radiation Therapy · Procedure: Tumor biopsy · Procedure: Peripheral blood draw
Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food
Also known as: Ibrance, PD 0332991
-Cetuximab must not be administered as an IV push or bolus
Also known as: Erbitux
-Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.
Also known as: Platinol-AQ, Platinol
-Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays
Also known as: IMRT
* Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy * If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline.
Baseline and post-treatment
Tumor Response Rate of Newly Diagnosed p16INK4a Negative, HPV-unrelated HNSCC to Neoadjuvant Palbociclib Monotherapy
* Tumor response rate is defined as the proportion of subjects who achieve a complete response (CR) or partial response (PR) based on RECIST criteria * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). * PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: 2 cycles (56 days)
Combined Local-regional Disease Relapse Risk and Distant Metastases Risk Following Completion of CRT
* Local-regional disease relapse, a binary variable (Yes vs. No). Local-regional disease relapse rate is defined as the proportion of subjects alive who have local-regional progressed disease at 18 months following completion of CRT, stratified by cohorts. * Distant metastases, a binary variable (Yes vs. No). Distant metastases rate is defined as the proportion of subjects alive who have distant metastases at 18 months following completion of CRT, stratified by cohorts.
Time frame: Through 18 months after completion of step 2
Median Progression-free Survival (PFS) (Stratified by Cohort) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy
-Progression-free survival (PFS), defined as the interval from the start of Step 2 (CRT) to the first documentation of disease progression or death from any cause or the end of follow-up, stratified by cohorts.
Time frame: Through 5 years after completion of step 2
Progression-free Survival (PFS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy
-Progression-free survival (PFS), defined as the days from the start of Step 2 (CRT) to the first documentation of disease progression or death from any cause or the end of follow-up
Time frame: Through 2 years after completion of step 2
Median Overall Survival (OS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy
-Overall survival (OS), defined as the days from the time of diagnosis to death from any cause or the end of follow-up
Time frame: Through 5 years after completion of step 2
Overall Survival of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy
-Overall survival (OS), defined as the days from the time of diagnosis to death from any cause or the end of follow-up
Time frame: Through 2 years after completion of step 2
Change in Genomic Alterations in Tumor Tissue
Tumor genomic alterations at baseline and at relapse will be compared to assess for potential mechanisms of primary or secondary resistance to palbociclib.
Time frame: At baseline and at time of disease relapse (up to 5 years)
Association Between Baseline Tumor CDKN2A and CCND1 Alterations and Tumor Response to Palbociclib Given Before CRT and Relapse After CRT
Number of participants with altered versus wild-type at baseline will be compared with response.
Time frame: At baseline and at time of disease relapse (up to 5 years)
| Milestone | Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib | Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib |
|---|---|---|
| Started | 19 | 7 |
| Completed | 18 | 7 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib | Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib |
|---|---|---|
| Started | 18 | 7 |
| Completed | 16 | 3 |
| Not completed | 2 | 4 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Disease progression | 1 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Poor performance status and nutrition | 0 | 1 |
| Milestone | Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib | Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib |
|---|---|---|
| Started | 16 | 3 |
| Completed | 11 | 2 |
| Not completed | 5 | 1 |
| Withdrew: Withdrawal after 3 cycles | 0 | 1 |
| Withdrew: Still receiving active treatment | 4 | 0 |
| Withdrew: Progressive disease after 2 cycles | 1 | 0 |
* Tumor response rate is defined as the proportion of subjects who achieve a complete response (CR) or partial response (PR) based on RECIST criteria * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). * PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| Participants | Step 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2 |
|---|---|
| Tumor Response Rate of Newly Diagnosed p16INK4a Negative, HPV-unrelated HNSCC to Neoadjuvant Palbociclib Monotherapy | 6 |
* Local-regional disease relapse, a binary variable (Yes vs. No). Local-regional disease relapse rate is defined as the proportion of subjects alive who have local-regional progressed disease at 18 months following completion of CRT, stratified by cohorts. * Distant metastases, a binary variable (Yes vs. No). Distant metastases rate is defined as the proportion of subjects alive who have distant metastases at 18 months following completion of CRT, stratified by cohorts.
| Participants | Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib | Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib |
|---|---|---|
| Local-regional disease relapse | 0 | 2 |
| Distant metastases | 4 | 1 |
| Both local-regional disease relapse and distant metastases | 1 | 0 |
-Progression-free survival (PFS), defined as the interval from the start of Step 2 (CRT) to the first documentation of disease progression or death from any cause or the end of follow-up, stratified by cohorts.
Results for this outcome have not been posted.
-Progression-free survival (PFS), defined as the days from the start of Step 2 (CRT) to the first documentation of disease progression or death from any cause or the end of follow-up
| Participants | Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib | Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib |
|---|---|---|
| Progression-free Survival (PFS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy | 13 | 3 |
-Overall survival (OS), defined as the days from the time of diagnosis to death from any cause or the end of follow-up
Results for this outcome have not been posted.
-Overall survival (OS), defined as the days from the time of diagnosis to death from any cause or the end of follow-up
| Participants | Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib | Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib |
|---|---|---|
| Overall Survival of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy | 16 | 5 |
Tumor genomic alterations at baseline and at relapse will be compared to assess for potential mechanisms of primary or secondary resistance to palbociclib.
Results for this outcome have not been posted.
Number of participants with altered versus wild-type at baseline will be compared with response.
Results for this outcome have not been posted.
Collected over Adverse events (AEs) collected for 56 days Step 1. Step 2 Cohort 1 & Cohort 2 collected 6 weeks. Step 3 collected from start of Step 3 through 30 days following the last day of treatment. If a patient went off treatment during Step 1 or Step 2, they were collected for an additional 30 days after treatment. Median AE follow-up 376.5 days (full range 61-486 days). Median all-cause mortality follow-up 596 days (full range 61 days-1573 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Step 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2 | 0/26 (0%) | 3/26 (11.5%) | 26/26 (100%) |
| Step 2 Cohort 1 (Cisplatin + IMRT) | 0/18 (0%) | 10/18 (55.6%) | 18/18 (100%) |
| Step 2 Cohort 2 (Cetuximab + IMRT) | 1/7 (14.3%) | 4/7 (57.1%) | 7/7 (100%) |
| Step 3 Adjuvant Palbociclib for Cohort 1 and Cohort 2 | 0/19 (0%) | 0/19 (0%) | 19/19 (100%) |
| Follow-up After Completion of Treatment | 8/26 (30.8%) | — | — |
| Event | Step 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2 | Step 2 Cohort 1 (Cisplatin + IMRT) | Step 2 Cohort 2 (Cetuximab + IMRT) | Step 3 Adjuvant Palbociclib for Cohort 1 and Cohort 2 | Follow-up After Completion of Treatment |
|---|---|---|---|---|---|
| Lung infectionRespiratory, thoracic and mediastinal disorders | 0/26 | 1/18 | 2/7 | — | — |
| Laryngeal edemaRespiratory, thoracic and mediastinal disorders | 0/26 | 3/18 | 0/7 | — | — |
| DysphagiaGastrointestinal disorders | 0/26 | 0/18 | 1/7 | — | — |
| FeverGeneral disorders | 0/26 | 1/18 | 1/7 | — | — |
| Catheter related infectionInfections and infestations | 0/26 | 0/18 | 1/7 | — | — |
| HypocalcemiaMetabolism and nutrition disorders | 0/26 | 0/18 | 1/7 | — | — |
| AspirationRespiratory, thoracic and mediastinal disorders | 2/26 | 2/18 | 1/7 | — | — |
| FallInjury, poisoning and procedural complications | 0/26 | 2/18 | 0/7 | — | — |
| DeliriumPsychiatric disorders | 0/26 | 2/18 | 0/7 | — | — |
| AnemiaBlood and lymphatic system disorders | 1/26 | 1/18 | 0/7 | — | — |
| Event | Step 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2 | Step 2 Cohort 1 (Cisplatin + IMRT) | Step 2 Cohort 2 (Cetuximab + IMRT) | Step 3 Adjuvant Palbociclib for Cohort 1 and Cohort 2 | Follow-up After Completion of Treatment |
|---|---|---|---|---|---|
| White blood cell decreasedInvestigations | 20/26 | 17/18 | 4/7 | 19/19 | — |
| Lymphocyte count decreasedInvestigations | 15/26 | 17/18 | 6/7 | 18/19 | — |
| AnemiaBlood and lymphatic system disorders | 23/26 | 17/18 | 6/7 | 15/19 | — |
| Neutrophil count decreasedInvestigations | 20/26 | 12/18 | 3/7 | 17/19 | — |
| Mucositis oralGastrointestinal disorders | 1/26 | 11/18 | 6/7 | 5/19 | — |
| FatigueGeneral disorders | 11/26 | 13/18 | 6/7 | 11/19 | — |
| Dry mouthGastrointestinal disorders | 1/26 | 15/18 | 5/7 | 13/19 | — |
| DysphagiaGastrointestinal disorders | 19/26 | 15/18 | 4/7 | 10/19 | — |
| Dermatitis radiationInjury, poisoning and procedural complications | 0/26 | 15/18 | 5/7 | 6/19 | — |
| Weight lossInvestigations | 7/26 | 14/18 | 4/7 | 10/19 | — |
| Age, Continuous(years) | Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib | Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib | Total |
|---|---|---|---|
| Median | 61 (44 to 72) | 66 (64 to 75) | 63 (44 to 75) |
| Sex: Female, Male(Participants) | Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib | Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib | Total |
|---|---|---|---|
| Female | 4 | 3 | 7 |
| Male | 15 | 4 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib | Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 19 | 7 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib | Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 16 | 6 | 22 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib | Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib | Total |
|---|---|---|---|
| United States | 19 | 7 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2018 to primary completion in Feb 2022, 45 months.
Results were first posted in Mar 2023, 1 year after primary completion.
Of 298 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 45 months is below that.
Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palbociclib
Squamous Cell Carcinoma of Head and Neck →
Washington University School of Medicine →